Abstract
Gene therapy is considered a feasible approach for the treatment and prevention of HIV/AIDS. Targeting both viral genes and host dependency factors can interfere with the viral lifecycle and prevent viral replication. A number of approaches have been taken to target these genes, including ribozymes, aptamers, and RNAi based therapies. A number of these therapies are now beginning to make their way into clinical trials and providing proof of principle that gene therapy is a safe and realistic option for treating HIV. Here, we focus on those therapies that have progressed along the pipeline to preclinical and clinical testing.
Keywords:
Clinical Trial HIV; Gene therapy HIV; RNAi HIV; aptamer HIV; ribozyme HIV.
Copyright © 2011.
MeSH terms
-
Anti-HIV Agents / metabolism
-
Anti-HIV Agents / therapeutic use*
-
Antigens, CD34 / metabolism
-
Antiretroviral Therapy, Highly Active
-
Aptamers, Nucleotide / metabolism
-
Aptamers, Nucleotide / therapeutic use
-
CD4-Positive T-Lymphocytes / metabolism
-
Clinical Trials as Topic
-
Genetic Therapy / methods*
-
Genetic Vectors / genetics
-
Genetic Vectors / metabolism
-
HIV / pathogenicity
-
HIV / physiology
-
HIV Infections / prevention & control
-
HIV Infections / therapy*
-
HIV Infections / virology
-
HIV Long Terminal Repeat
-
Humans
-
RNA Interference
-
RNA, Catalytic / metabolism
-
RNA, Catalytic / therapeutic use
-
RNA, Small Interfering / metabolism
-
RNA, Small Interfering / therapeutic use
-
Virus Replication
Substances
-
Anti-HIV Agents
-
Antigens, CD34
-
Aptamers, Nucleotide
-
RNA, Catalytic
-
RNA, Small Interfering
-
hairpin ribozyme